SLSBio Quarterly Report: Revenue Plunges 45%, Operating Loss Widens, Listing Eligibility Review Poses Risk to Shareholder Value

Revenue Decline: Q1 2026 revenue of 957.7M KRW fell 45.4% YoY from 1.75B KRW; operating loss widened to -950.4M KRW (vs -219.5M KRW); net loss of -938.7M KRW (vs -198.7M KRW).
Financial Deterioration: Debt ratio rose to 50.6% from 47.1%; equity decreased 12.3% to 6.70B KRW; cash and equivalents slightly down to 260.6M KRW; operating cash flow turned deeply negative at -796.8M KRW from +195.5M KRW.
Listing Eligibility Review Risk: Subject to a substantive listing review by Korea Exchange with improvement period until August 31, 2026; failure may lead to delisting.
Unfaithful Disclosure Entity: Designated as an unfaithful disclosure entity in December 2025 due to reversal of asset acquisition decision, receiving 3 penalty points.
No Shareholder Returns: No dividends since 2024; no share buyback or cancellation plans.
[AI Summary]This quarterly report highlights SLSBio's deteriorating operations and financial health, with the listing eligibility review posing a significant risk to shareholder value. Continued revenue decline and widening losses, coupled with potential capital erosion and liquidity concerns, represent key investment risks.